Results 181 to 190 of about 66,344 (289)

Case Report: Voglibose-induced persistent leukopenia in a patient with type 2 diabetes. [PDF]

Front Endocrinol (Lausanne)
Guo JW, Yan JH, Chang LS, Cai S, Jiang YQ, Chen FQ.   +5 more
europepmc   +1 more source

Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial

MedComm, Volume 7, Issue 11, November 2026.
This study enrolled 70 HER2‐negative, unresectable stage III/IV gastric/gastroesophageal junction adenocarcinoma patients with over 6‐month survival, divided into RNPLS and NPLS groups (n = 35 each). Both groups received 21‐day‐cycle chemotherapy with lobaplatin, nab‐paclitaxel, and S‐1, while RNPLS additionally used ramucirumab.
Juan Wang, Wei Wang, Guanghui Xu, Shushang Liu, Longxing Jiao, Shu Wang, Chaosheng Peng, Yuxuan Ma, Xin Liu, Huade Huo, Haolin Li, Xiaohua Li, Jianjun Yang   +12 more
wiley   +1 more source

Potential vascular confound in GPR84-PET imaging following systemic LPS administration. [PDF]

Proc Natl Acad Sci U S A
Zoghbi SS, Innis RB.
europepmc   +1 more source

Efficacy and Safety of Lucitanib in Advanced Thymic Carcinoma: A Randomized Phase II Trial

MedComm, Volume 7, Issue 11, November 2026.
In this randomized phase II trial, 68 patients with advanced thymic carcinoma after chemotherapy received lucitanib (n = 46) or placebo (n = 22). Median PFS was 5.8 versus 3.7 months by IRC (HR: 0.60; p = 0.105) and 6.6 versus 1.9 months by investigators (HR: 0.53; p = 0.031). Hypertension was the most common grade 3 TRAE (50%).
Wentao Fang, Caicun Zhou, Changlu Wang, Kailiang Wu, Jianhua Fu, Xiaoyan Lin, Helong Zhang, Jianhua Chen, Peng Zhang, Yiping Zhang, Peng Tang, Yulong Zheng, Yanping Liu, Xiuyi Zhi, Zhancheng Gao, Qingxia Fan, Huiming Cai, Fugen Li, Xiaoning Guo, Bo Zhang, Rongji Mu, Zhangsheng Yu   +21 more
wiley   +1 more source

Correction: Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada

Frontiers in Immunology
John Gill, Andrew A. House, Zain Chagla, Jean Tchervenkov, S. Joseph Kim, Amanda Vinson, Carlos Cervera, Paul A. Keown, Sonia Lai Wing Sun, Christina Khoury, Christiane Ghakis   +10 more
doaj   +1 more source

Severe Thrombocytopenia and Leukopenia as the Initial Manifestations of Brucella melitensis Bacteremia: A Case Report. [PDF]

Cureus
Pico Mendoza C, Hernandez Soto LE, Gomez Zapata JF, Vazquez Enriquez LF, Dominguez Romo K.   +4 more
europepmc   +1 more source

Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ‐B3101) in Pediatric Patients With Relapsed/Refractory Anaplastic Lymphoma Kinase‐Positive Anaplastic Large‐Cell Lymphoma: A Phase I Study

MedComm, Volume 7, Issue 11, November 2026.
This Phase I study evaluated unecritinib (TQ‐B3101) in pediatric patients with relapsed/refractory ALK+ anaplastic large‐cell lymphoma. Unecritinib showed a manageable safety profile without dose‐limiting toxicities and achieved remarkable efficacy, with a 100% overall response rate.
Suying Lu, Junting Huang, Ruiqing Cai, Yan Gao, Jia Zhu, Juan Wang, Yi Que, Zijun Zhen, Feifei Sun, Huiqiang Huang, Yizhuo Zhang   +10 more
wiley   +1 more source

Erratum to "Pharmacogenetic Risk Factors for Thiopurine-Induced Leukopenia in Patients with Inflammatory Bowel Disease" by Boo EK, et al. (Yonsei Med J 2026;67(8):603-615). [PDF]

Yonsei Med J
europepmc   +1 more source

Clozapine‐Associated Neutropenia With COVID‐19 Infection and the Role of Filgrastim

Progress in Neurology and Psychiatry, Volume 30, Issue 4, November 2026.
ABSTRACT Clozapine is the gold standard, evidence‐based treatment of choice for treatment‐resistant schizophrenia. However, clozapine can induce serious, life‐threatening adverse effects, including neutropenia and agranulocytosis. There is accumulating evidence to suggest that rechallenging with clozapine should be considered in most patients with ...
Devender Singh Yadav
wiley   +1 more source

Probable Stevens–Johnson Syndrome During Taletrectinib Treatment After Crizotinib‐Related Rash in ROS1‐Positive Lung Cancer

Respirology Case Reports, Volume 14, Issue 11, November 2026.
Probable Stevens–Johnson syndrome developed during taletrectinib treatment after a preceding crizotinib‐related Grade 3 rash in a patient with ROS1‐rearranged lung adenocarcinoma. This case highlights that severe cutaneous adverse reactions should be considered when fever and neutropenia occur during ROS1‐TKI therapy.
Hirotoshi Yasui, Ryo Fukaura, Miyu Misaki, Souma Usui, Saho Katsumata, Ryo Niimi, Ko Ohara, Kaito Sano, Yasutaka Mori, Tomofumi Shibata, Yasutaka Fukui, Mitsuru Odate, Yasushi Makino   +12 more
wiley   +1 more source